HealthBreaking
FDA orders GLP-1 drugmakers to add warning on rare eye condition
By Mantle News
Coverage spectrum
Covered by 4 outlets. No right-leaning outlet that Mantle follows has covered it yet.
5 articles in total. The spectrum counts each outlet once and leaves opinion out. How we measure bias
The US Food and Drug Administration said on Monday that makers of GLP-1 drugs, including Ozempic, Zepbound, Wegovy and Mounjaro, must add a warning about a rare eye condition, nonarteritic anterior ischemic optic neuropathy (NAION), to their labels. NAION affects the optic nerve and can cause sudden vision loss that the reports describe as permanent. The FDA said it began looking into a possible link after a 2024 study in JAMA Ophthalmology found that diabetes patients prescribed semaglutide were four times as likely to develop NAION. Several medical studies have found an elevated risk for people taking GLP-1 drugs. Novo Nordisk and Eli Lilly said patient safety is their top priority.
Headline and summary written by Mantle’s AI from the coverage below, under published rules. Editors read every story. How this works
What happened
Key points
Each point shows who reports it, from Far Left to Far Right.
The FDA is requiring makers of GLP-1 drugs to add a warning about the rare eye condition NAION to their labels.
Reported byLeft2Center1See the outletsHide the outlets
- Left
- NBC News, CNN
- Center
- Financial Times
The requirement covers Ozempic, Zepbound, Wegovy and Mounjaro, along with several older GLP-1 diabetes medications.
One outletNBC News· Left
NAION affects the optic nerve and can cause sudden vision loss that is described as permanent.
Reported byLeft1Center1See the outletsHide the outlets
- Left
- NBC News
- Center
- Financial Times
Several medical studies have found an elevated risk of NAION in people taking GLP-1 drugs.
Reported byLeft1Center2See the outletsHide the outlets
- Left
- NBC News
- Center
- MarketWatch, Financial Times
The FDA began examining a possible link after a 2024 JAMA Ophthalmology study linked semaglutide to a higher NAION rate in diabetes patients.
One outletNBC News· Left
Novo Nordisk and Eli Lilly said patient safety is their top priority.
One outletNBC News· Left
How each side tells it
Compare views
Every outlet reports a link between GLP-1 drugs and NAION, a rare eye condition that can cause vision loss. Left outlets center the FDA's new warning order and sudden blindness, while center outlets stress the regulator action in the FT and the studies behind the risk in MarketWatch.
the left
2 outlets
Headlines lead with the FDA ordering a new warning and stress the sudden blindness risk of a rare eye condition, naming the drugs Ozempic and Zepbound.
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
NBC NewsLeftAll left-leaning headlines the center
3 outlets
Center headlines frame the warning either as a regulator order to drugmakers (FT) or as a possible risk shown by medical studies (MarketWatch), with the FDA less central in the second.
US regulator orders makers of weight-loss drugs to carry Sensational language“blindness risk”The condition is described in the same article as causing permanent vision loss, so blindness overstates the stated risk.More neutral: vision loss riskDisagree with this highlight? warning
Financial TimesCenterAll center headlines the right
No coverage yet
No right-leaning outlet that Mantle follows has covered this story yet. That absence is part of the picture.
The words they chose
Language to notice
Words that carry a judgement beyond the facts. Tap a highlighted word anywhere on the page to see why.
Left0
No loaded words in its own voice.
Center1
blindness risk
Right
Has not covered this story.
In the outlets’ own words
Sensational language
blindness riskMore neutral: vision loss risk
The condition is described in the same article as causing permanent vision loss, so blindness overstates the stated risk.
US regulator orders makers of weight-loss drugs to carry blindness risk warning
Used byFinancial Times (Center)
See for yourself
Side by side
What each side leads with and what it leaves out. Open a side to read its headlines.
From the left
2 outletsLeads with
- FDA-ordered warning label
- sudden blindness risk
- named brands Ozempic and Zepbound
See the 2 headlines from the leftHide the headlines
- NBC NewsLeft
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
The Food and Drug Administration said Monday that GLP-1 drugmakers must add a warning label about a rare eye condition that can cause sudden blindness.
- CNNLeft
US FDA orders new eye risk warnings for Ozempic, Zepbound
The US health regulator on Monday informed patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes. …
From the center
3 outletsLeads with
- regulator order to drugmakers
- permanent vision loss risk
- medical studies showing elevated risk
See the 3 headlines from the centerHide the headlines
FDA announces new safety labeling for GLP-1 RA medications
The FDA announced new safety labeling for GLP-1 RA medications such as Ozempic, warning of a potential increased risk for a rare eye condition.
- MarketWatchCenter
Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
Several medical studies have found that people taking GLP-1 medications have an elevated risk for nonarteritic anterior ischemic optic neuropathy, or NAION.
- Financial TimesCenter
US regulator orders makers of weight-loss drugs to carry Sensational language“blindness risk”The condition is described in the same article as causing permanent vision loss, so blindness overstates the stated risk.More neutral: vision loss riskDisagree with this highlight? warning
Food and Drug Administration cites increased risk of rare eye condition that can cause permanent vision loss in users of GLP-1s
From the right
0 outletsNo right-leaning outlet that Mantle follows has covered this story yet. That absence is part of the picture.
The stories you read build My Mix, a private picture of which sides cover the stories you choose, kept on this device. What is My Mix?
The left is Far Left and Left together. The right is Right and Far Right together. Every outlet keeps its own five-point rating.
Who reported it when
How the coverage built up
Left
First to report
CNN, Nov 9, 11:43 AM EST
Center
37 min later
Its first report, Nov 9, 12:20 PM EST
Right
No report yet
From the outlets Mantle follows
See the order the outlets reported inHide the order
- CNNLeftNov 9, 11:43 AM EST
- Financial TimesCenterNov 9, 12:20 PM EST
- MarketWatchCenterNov 9, 12:52 PM EST
- NBC NewsLeftNov 9, 1:14 PM EST
- United Press InternationalCenterNov 9, 2:44 PM EST
Times are the ones the outlets published in their own feeds, in Eastern time. Opinion is left out.
Read next
More on Health
PoliticsDeveloping
Former HHS adviser Calley Means accuses Trump officials of favoring industry over health
11 outlets
23 outlets
Next in today’s stories
Business & MarketsDeveloping
Nvidia CEO Jensen Huang faces scandal over admitted affair with alleged Chinese spy
3 outlets
Next in today’s stories
Climate & EnvironmentDeveloping
Senate to take up bipartisan energy permitting bill that Trump has urged it to pass
5 outletsQuiet in the center
A story one side mostly skipped
Climate & EnvironmentDeveloping
UN COP31 climate summit opens in Antalya, Turkey, with talks on electrification
13 outletsQuiet on the right